Clinical

Investigators examined medical records spanning 3 decades to look at the effect of poorly differentiated tumor size on outcomes in survival in hepatocellular carcinoma (HCC).

This pivotal phase 3 trial led to the recent approval of lonapegsomatropin for growth hormone deficiency.

Crigler-Najjar Syndrome Type 1 is an ultra-rare disease where treatment relies on a liver transplant or full-day phototherapy sessions.

In a recent study, researchers were able to show how different evolutionary forces in aging blood stem cells impact whether or not someone develops acute myeloid leukemia (AML), offering insight into those at higher risk of the disease.

David J. Reeves, PharmD, BCOP, of Butler University discusses encouraging results from a recent trial, along with safety questions about the types of patients who weren't studied but are likely to have small cell lung cancer.

Study authors found that knowing a patient’s minimal residual disease status can help pinpoint the right multiple myeloma therapy to improve overall and progression-free survival.

Patients with BRAF-V600 mutated metastatic melanoma have new treatment options to consider, but scientists are still waiting on additional data to help choose which first-line treatments are best for which patients.

Results of a data analysis found once-daily zanubrutinib dosing in patients with mantle cell lymphoma (MCL) is safe and effective.

A case report details the presentation of systemic lupus erythematous in a young, previously healthy individual.

Two posters reviewed impairment after COVID-19 infection and the use of pulmonary rehabilitation to address the symptoms.

A review of cases using MRI with and without contrast agent found perfect or near-perfect agreement in most cases when evaluating patients with short stature for growth hormone deficiency.

Gefapixant successfully improved quality-of-life and reduced cough severity for patients with chronic cough vs placebo, according to 2 posters.

Health care and research need to do a better job of taking into account sex and gender differences that can affect disease, healthy behaviors, and care delivery, according to speakers at the European Respiratory Society International Congress 2021.

Dual bronchodilators have been shown to broadly improve symptoms and quality of life (QOL) in patients with chronic obstructive pulmonary disease (COPD).

During the pandemic, interest in home monitoring grew, and research has shown it can be feasible for patients with interstitial lung disease, according to a presentation at the European Respiratory Society International Congress 2021.

The chief of medical oncology and hematology at Bryn Mawr Hospital and associate principal investigator for Main Line Health's NCI Community Oncology Research Program discusses therapeutic advances along with ongoing challenges in enrolling patients with small cell lung cancer (SCLC) in clinical trials.

Ruxolitinib is increasingly being used in patients with graft-vs-host-disease (GVHD); a recent study found a link with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with GVHD treated with the therapy.

For patients with diffuse large B-cell lymphoma (DLBCL), PET/CT scans conducted in the first cycle of salvage therapy can predict for response, according to a study.

A review looks at techniques to monitor minimal residual disease (MRD) in patients with multiple myeloma (MM).

Results of the SAFINONMOTOR open-label study found that safinamide was safe and effective in improving pain of patients with Parkinson disease at 6 months.

The murine study, which assessed the combination of foretinib and an anti–PD-1 antibody, found that the regimen enhanced antitumor activity, offering promise in a cancer that has seen less success with immunotherapies than others.

Investigators identified serial liquid biopsy as an effective tool for identifying mutational changes of RAS genes in patients with metastatic colorectal cancer (mCRC) who have undergone antiangiogenic therapy.

Most studies to date that show efficacy with ruxolitinib in this setting have been in adult patients.

The product, lonapegsomatropin, is a sustained-release formulation and could replace daily injections.

The study, using a BCR/ABL1 assay, found that the novel method is able to detect minimal residual disease (MRD) in a larger range of patients compared with quantitative real‐time polymerase chain reaction, the method currently used to detect MRD.

The approval of zanubrutinib makes it just the second therapy indicated for this rare type of lymphoma.

The findings, if confirmed in subsequent research, could prove to have significant implications, as only a small subset of patients with chronic lymphocytic leukemia (CLL) respond to chimeric antigen receptor (CAR) T-cell therapy.

The European Respiratory Society International Congress 2021 will feature a wide array of topics, such as gender and respiratory health, the impact of climate change, and management and treatment of chronic cough, but there remains a strong focus on the COVID-19 pandemic, its intersection with respiratory care and treatment of infection.

Results of a multicenter study showed 43% of patients with advanced melanoma treated with anti–programmed cell death 1 therapy experienced chronic complications.

A review of treatment options in diffuse large B-cell lymphoma (DLBCL) addresses common subtypes and patient response to standard of care.